<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-109800" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tyrosine Kinase Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thomson</surname>
            <given-names>Robert J.</given-names>
          </name>
          <aff>McGovern Medical School</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moshirfar</surname>
            <given-names>Majid</given-names>
          </name>
          <aff>University of Utah/John Moran Eye Center; Hoopes Vision/HDR Research Center; Utah Lions Eye Bank</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ronquillo</surname>
            <given-names>Yasmyne</given-names>
          </name>
          <aff>Hoopes Vision Research Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Thomson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Majid Moshirfar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yasmyne Ronquillo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-109800.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tyrosine kinase inhibitors (TKI) are a group of pharmacologic agents that disrupt the signal transduction pathways of protein kinases by several modes of inhibition. This activity will review the currently available drugs, their mechanism of action, routes of administration, indications, contraindications, and adverse effects.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the different types of tyrosine kinase inhibitor (TKI) drugs and the currently available TKIs.</p></list-item><list-item><p>Describe the mechanism of action of tyrosine kinase inhibitors.</p></list-item><list-item><p>Summarize the indications and contraindications for each type of tyrosine kinase inhibitor.</p></list-item><list-item><p>Review the adverse effects and toxicity of tyrosine kinase inhibitors.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=109800&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=109800">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-109800.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Mutations, dysregulation, and overexpression of protein kinases are involved in a multitude of disease processes. Around 1 in every 40 human genes codes for a protein kinase and nearly half of those genes map to either disease loci or cancer amplicons.<xref ref-type="bibr" rid="article-109800.r1">[1]</xref> Interest in protein kinase inhibitors began with the FDA approval of the tyrosine kinase inhibitor (TKI) imatinib in 2001. Imatinib is an oral chemotherapy medication designed to target the BCR-Abl hybrid protein, a tyrosine kinase signaling protein produced in patients with Philadelphia-chromosome-positive chronic myelogenous leukemia. Since the introduction of Imatinib, the application of TKIs has been ever-expanding, particularly for cancer treatment, due to tyrosine kinases' critical roles in cellular signaling.<xref ref-type="bibr" rid="article-109800.r2">[2]</xref><xref ref-type="bibr" rid="article-109800.r3">[3]</xref></p>
        <p>Tyrosine kinase enzymes (TKs) can be categorized into receptor tyrosine kinases (RTKs), non-receptor tyrosine kinases (NRTKs), and a small group of dual-specificity kinases (DSK) which can phosphorylate serine, threonine, and tyrosine residues. RTKs are transmembrane receptor that includes vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), insulin receptor (InsR) family, and the ErbB receptor family, which includes epidermal growth factor receptors (EGFR) and the human epidermal growth factor receptor-2 (HER2). NRTKs are cytoplasmic proteins that consist of nine families, including Abl, Ack, Csk, Fak, Fes/Fer, Jak, Src, Syk/Zap70, and Tec, with the addition of Brl/Sik, Rak/Frk, Rlk/Txk, and Srm, which fall outside the nine defined families. The most notable example of DSKs is the mitogen-activated protein kinase kinases (MEKs), which are principally involved in the MAP pathways.<xref ref-type="bibr" rid="article-109800.r1">[1]</xref><xref ref-type="bibr" rid="article-109800.r4">[4]</xref><xref ref-type="bibr" rid="article-109800.r5">[5]</xref></p>
        <p>As of now, there are over 50 FDA-approved TKIs. Comprehensive lists of FDA-approved TKIs with additional information are available at NIH PubChem and FDA.gov. Due to the broad reach of this topic and the rapid development of new drugs, this list is not fully comprehensive.</p>
        <table-wrap id="article-109800.table0" position="float" orientation="portrait">
          <table>
            <tbody>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p>&#x000a0;&#x000a0; <bold>TKI</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Target</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p><bold>Indication</bold></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Deucravacitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>TYK2</p>
</td>
                <td rowspan="1" colspan="1">
<p>moderate-to-severe plaque psoriasis</p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Avapritinib&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; </bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>PDGFR&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</p>
</td>
                <td rowspan="1" colspan="1">
<p>GIST (gastrointestinal stromal tumors) <xref ref-type="bibr" rid="article-109800.r6">[6]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Capmatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>c-MET</p>
</td>
                <td rowspan="1" colspan="1">
<p>NSCLC (non-small cell lung cancer) <xref ref-type="bibr" rid="article-109800.r7">[7]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Pemigatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>FGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Cholangiocarcinoma with FGFR2 fusions or rearrangements <xref ref-type="bibr" rid="article-109800.r8">[8]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Ripretinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>KIT/PDGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>GIST <xref ref-type="bibr" rid="article-109800.r9">[9]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Selpercatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>RET</p>
</td>
                <td rowspan="1" colspan="1">
<p>NSCLC and thyroid cancer <xref ref-type="bibr" rid="article-109800.r10">[10]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Selumetinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>MEK1/2</p>
</td>
                <td rowspan="1" colspan="1">
<p>Neurofibromatosis type 1 <xref ref-type="bibr" rid="article-109800.r11">[11]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Tucatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Her2</p>
</td>
                <td rowspan="1" colspan="1">
<p>HER2-positive breast cancer <xref ref-type="bibr" rid="article-109800.r12">[12]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Entrectinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>TRKA/B/C, ROS1</p>
</td>
                <td rowspan="1" colspan="1">
<p>ROS1-positive NSCLC, Solid tumors with NTRK fusion proteins <xref ref-type="bibr" rid="article-109800.r13">[13]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Erdafitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>FGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Urothelial bladder cancers <xref ref-type="bibr" rid="article-109800.r14">[14]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Fedratinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>JAK2</p>
</td>
                <td rowspan="1" colspan="1">
<p>Myelofibrosis <xref ref-type="bibr" rid="article-109800.r15">[15]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Pexidartinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>CSF1R</p>
</td>
                <td rowspan="1" colspan="1">
<p>Tenosynovial giant cell tumors <xref ref-type="bibr" rid="article-109800.r16">[16]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Upadacitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>PDGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>GIST <xref ref-type="bibr" rid="article-109800.r17">[17]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Zanubrutinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>BTK</p>
</td>
                <td rowspan="1" colspan="1">
<p>Mantle cell lymphoma <xref ref-type="bibr" rid="article-109800.r18">[18]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Baricitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>JAK1/2</p>
</td>
                <td rowspan="1" colspan="1">
<p>Rheumatoid arthritis <xref ref-type="bibr" rid="article-109800.r19">[19]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Binimetinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>MEK1/2</p>
</td>
                <td rowspan="1" colspan="1">
<p>Melanoma <xref ref-type="bibr" rid="article-109800.r20">[20]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Dacomitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>EGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p><italic toggle="yes">EGFR</italic>-mutant NSCLC <xref ref-type="bibr" rid="article-109800.r21">[21]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Fostamatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Syk</p>
</td>
                <td rowspan="1" colspan="1">
<p>Chronic immune thrombocytopenia <xref ref-type="bibr" rid="article-109800.r22">[22]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Gilteritinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Flt</p>
</td>
                <td rowspan="1" colspan="1">
<p>Acute myelogenous leukemia (AML) <xref ref-type="bibr" rid="article-109800.r23">[23]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Larotrectinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>TRKA/B/C</p>
</td>
                <td rowspan="1" colspan="1">
<p>Solid tumors with NTRK fusion proteins <xref ref-type="bibr" rid="article-109800.r24">[24]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Lorlatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK</p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK-positive NSCLC <xref ref-type="bibr" rid="article-109800.r25">[25]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Acalabrutinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>BTK</p>
</td>
                <td rowspan="1" colspan="1">
<p>Mantle cell lymphoma, chronic lymphocytic&#x000a0; leukemia (CLL), small lymphocytic lymphomas <xref ref-type="bibr" rid="article-109800.r26">[26]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Brigatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK</p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK-positive NSCLC <xref ref-type="bibr" rid="article-109800.r21">[21]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Midostaurin</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>Flt3</p>
</td>
                <td rowspan="1" colspan="1">
<p>AML, advanced systemic mastocytosis, mast cell leukemia <xref ref-type="bibr" rid="article-109800.r27">[27]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Neratinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>HER2</p>
</td>
                <td rowspan="1" colspan="1">
<p>HER2-positive breast cancer <xref ref-type="bibr" rid="article-109800.r21">[21]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Alectinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK, RET</p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK-positive NSCLC <xref ref-type="bibr" rid="article-109800.r28">[28]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Cobimetinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>MEK1/2</p>
</td>
                <td rowspan="1" colspan="1">
<p>combination therapy with vemurafenib for<italic toggle="yes"> BRAF</italic>-positive melanoma <xref ref-type="bibr" rid="article-109800.r29">[29]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Lenvatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>VEGFR, RET</p>
</td>
                <td rowspan="1" colspan="1">
<p>Differentiated thyroid cancer <xref ref-type="bibr" rid="article-109800.r30">[30]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Osimertinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>EGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>NSCLC <xref ref-type="bibr" rid="article-109800.r31">[31]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Ceritinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK</p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK-positive NSCLC resistant to crizotinib <xref ref-type="bibr" rid="article-109800.r32">[32]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Nintedanib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>FGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Idiopathic pulmonary fibrosis <xref ref-type="bibr" rid="article-109800.r33">[33]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Afatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>EGFR, HER2, ErB4</p>
</td>
                <td rowspan="1" colspan="1">
<p>NSCLC <xref ref-type="bibr" rid="article-109800.r31">[31]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Ibrutinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>BTK</p>
</td>
                <td rowspan="1" colspan="1">
<p>CLL, graft vs. host disease, mantle cell lymphoma, marginal zone lymphoma <xref ref-type="bibr" rid="article-109800.r26">[26]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Trametinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>MEK1/2</p>
</td>
                <td rowspan="1" colspan="1">
<p>Melanoma <xref ref-type="bibr" rid="article-109800.r34">[34]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Axitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>VEGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Advanced renal cell carcinoma <xref ref-type="bibr" rid="article-109800.r35">[35]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Bosutinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>BCR-Abl</p>
</td>
                <td rowspan="1" colspan="1">
<p>Chronic myelogenous leukemia (CML) <xref ref-type="bibr" rid="article-109800.r36">[36]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Cabozantinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>RET, VEGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Advanced medullary thyroid cancer, hepatocellular and renal cell carcinoma <xref ref-type="bibr" rid="article-109800.r37">[37]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Ponatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>BCR-Abl</p>
</td>
                <td rowspan="1" colspan="1">
<p>Philadelphia chromosome-positive CML or acute lymphoblastic leukemia (ALL) <xref ref-type="bibr" rid="article-109800.r36">[36]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Regorafenib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>VEGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Colorectal cancer and hepatocellular carcinoma, GIST <xref ref-type="bibr" rid="article-109800.r37">[37]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Tofacitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>JAK3</p>
</td>
                <td rowspan="1" colspan="1">
<p>Rheumatoid arthritis <xref ref-type="bibr" rid="article-109800.r19">[19]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Crizotinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK, ROS1</p>
</td>
                <td rowspan="1" colspan="1">
<p>ALK or ROS1-positive NSCLC <xref ref-type="bibr" rid="article-109800.r37">[37]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Ruxolitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>JAK1/2/3, Tyk</p>
</td>
                <td rowspan="1" colspan="1">
<p>Myelofibrosis, polycythemia vera <xref ref-type="bibr" rid="article-109800.r37">[37]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Vandetanib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>VEGFR2</p>
</td>
                <td rowspan="1" colspan="1">
<p>Medullary thyroid cancer <xref ref-type="bibr" rid="article-109800.r37">[37]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Pazopanib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>VEGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Renal cell carcinoma, soft tissue sarcomas <xref ref-type="bibr" rid="article-109800.r37">[37]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Lapatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>EGFR, HER2</p>
</td>
                <td rowspan="1" colspan="1">
<p>HER2-positive breast cancer <xref ref-type="bibr" rid="article-109800.r21">[21]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Nilotinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>BCR-Abl</p>
</td>
                <td rowspan="1" colspan="1">
<p>Philadelphia chromosome-positive CML <xref ref-type="bibr" rid="article-109800.r36">[36]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Dasatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>BCR-Abl</p>
</td>
                <td rowspan="1" colspan="1">
<p>CML <xref ref-type="bibr" rid="article-109800.r36">[36]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Sunitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>VEGFR2</p>
</td>
                <td rowspan="1" colspan="1">
<p>GIST, pancreatic neuroendocrine tumors, renal cell carcinomas <xref ref-type="bibr" rid="article-109800.r38">[38]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Sorafenib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>VEGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Hepatocellular carcinoma, renal cell carcinoma, differentiated thyroid cancer <xref ref-type="bibr" rid="article-109800.r3">[3]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Erlotinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>EGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>NSCLC, pancreatic cancer <xref ref-type="bibr" rid="article-109800.r31">[31]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Gefitinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>EGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>NSCLC <xref ref-type="bibr" rid="article-109800.r31">[31]</xref></p>
</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x000a0;</td>
                <td rowspan="1" colspan="1">
<p><bold>Imatinib</bold></p>
</td>
                <td rowspan="1" colspan="1">
<p>BCR-Abl, KIT, PGFR</p>
</td>
                <td rowspan="1" colspan="1">
<p>Philadelphia chromosome-positive CML or ALL, aggressive systemic mastocytosis, chronic eosinophilic leukemia, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, GIST, myelodysplastic/myeloproliferative disease <xref ref-type="bibr" rid="article-109800.r36">[36]</xref><xref ref-type="bibr" rid="article-109800.r39">[39]</xref></p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-109800.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>As a whole, tyrosine kinases phosphorylate specific amino acids on substrate enzymes, which subsequently alter signal transduction leading to downstream changes in cellular biology. The downstream signal transduction set off by TKs can modify cell growth, migration, differentiation, apoptosis, and death. Constitutive activation or inhibition, either by mutations or other means, can lead to dysregulated signal cascades, potentially resulting in malignancy and other pathologies.<xref ref-type="bibr" rid="article-109800.r4">[4]</xref><xref ref-type="bibr" rid="article-109800.r40">[40]</xref> Therefore, blocking these initial signals via TKIs can prevent the aberrant action of the mutated or dysfunctional TKs.</p>
        <p>Despite the diverse primary amino acid sequences, human kinases share similar 3D structures, particularly when it comes to the ATP-binding pocket located in the catalytically active region. The starting amino acid sequence (ASP-Phe-Gly or DFG) of the flexible activation loop that controls access to the activation site is also typically conserved.<xref ref-type="bibr" rid="article-109800.r41">[41]</xref></p>
        <p>Kinase inhibitors are either irreversible or reversible. The irreversible kinase inhibitors tend to covalently bind and block the ATP site resulting in irreversible inhibition. The reversible kinase inhibitors can further subdivide into four major subtypes based on the confirmation of the binding pocket as well as the DFG motif.<xref ref-type="bibr" rid="article-109800.r3">[3]</xref><xref ref-type="bibr" rid="article-109800.r42">[42]</xref></p>
        <p>Below are listed various binding modes of TKIs.<xref ref-type="bibr" rid="article-109800.r3">[3]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type I inhibitors</bold>: competitively bind to the ATP-binding site of active TKs. The arrangement of the DFG motif in type I inhibitors has the aspartate residue facing the catalytic site of the kinase.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type II inhibitors</bold>: bind to inactive kinases, usually at the ATP-binding site. The DFG motif in type II inhibitors protrudes outward away from the ATP-binding site. Due to the outward rotation of the DFG motif, many type II inhibitors can also exploit regions adjacent to the ATP-binding site that would otherwise be inaccessible.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type III inhibitors</bold>: do not interact with the ATP-binding pocket. Type III inhibitors exclusively bind to allosteric pockets adjacent to the ATP-binding region.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type IV inhibitors</bold>: bind allosteric sites far removed from the ATP-binding pocket.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type V inhibitors</bold>: refer to a proposed subset of kinase inhibitors that exhibit multiple binding modes.<xref ref-type="bibr" rid="article-109800.r43">[43]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-109800.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Nearly all TKIs are effective when taken orally. Therapeutic loading and maintenance dosages are unique to each drug and should require unique dosing for each patient. When administering specific TKIs, many factors can contribute to reduced potency and the development of acquired resistance. These factors include such as whether or not food intake affects bioavailability, the mechanism of drug metabolism and elimination, liver and kidney function, drug-drug interactions, the presence of other medications that alter stomach pH, and patient demographics.<xref ref-type="bibr" rid="article-109800.r44">[44]</xref><xref ref-type="bibr" rid="article-109800.r45">[45]</xref><xref ref-type="bibr" rid="article-109800.r46">[46]</xref></p>
      </sec>
      <sec id="article-109800.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse events of TKIs are usually dose-based, with broad side effect profiles unique to each drug. However, due to similarities in drug targets, different classes of TKIs can have similar side effect profiles. Clinicians use BCR-Abl and KIT inhibitors to treat Philadelphia chromosome-positive CML and GIST, respectively.<xref ref-type="bibr" rid="article-109800.r47">[47]</xref> Both KIT and BCR-Abl inhibitors, Imatinib, in particular, are known to cause adverse cutaneous drug reactions.<xref ref-type="bibr" rid="article-109800.r48">[48]</xref></p>
        <p>EGFRs are a large family of RTKs associated with several cancers, including NSCL, breast, colorectal, pancreatic, esophageal, and head-and-neck cancers. The most common severe adverse effects associated with EGRF inhibitors are related to cutaneous adverse drug reactions.<xref ref-type="bibr" rid="article-109800.r48">[48]</xref><xref ref-type="bibr" rid="article-109800.r49">[49]</xref> The reason for this association is likely due to EGFRs&#x02019; role in normal skin integrity. Inhibition of EGFR hinders integumental function leading to dysfunctional epidermal differentiation and re-epithelialization, resulting in skin erosions.<xref ref-type="bibr" rid="article-109800.r49">[49]</xref></p>
        <p>Angiogenesis is a critical step in cancer growth. VEGF is a key inducer of pathological angiogenesis expressed in nearly all human tumors.<xref ref-type="bibr" rid="article-109800.r50">[50]</xref> Due to VEGF&#x02019;s role in blood vessel survival and plasticity,&#x000a0;TKIs that inhibit VEGFR carry associations with several cardiovascular toxicities, particularly hypertension.<xref ref-type="bibr" rid="article-109800.r51">[51]</xref><xref ref-type="bibr" rid="article-109800.r52">[52]</xref> This toxicity is likely because VEGF is necessary for adequate nitric oxide production. Inhibition of VEGF, therefore, results in elevated systemic vascular resistance.<xref ref-type="bibr" rid="article-109800.r53">[53]</xref><xref ref-type="bibr" rid="article-109800.r54">[54]</xref> Because VEGF is vital to endothelial cell survival, anti-VEGF therapy can diminish the integrity and regenerative capacity of endothelial cells, causing pro-coagulant changes. The long-term weakening and diminished integrity of blood vessel walls can eventually lead to thrombosis and hemorrhage.<xref ref-type="bibr" rid="article-109800.r55">[55]</xref> Other adverse events associated with VEGFR TKIs include: renal injury, left ventricular dysfunction, cerebral and intestinal hemorrhage, cardiac ischemia, thrombosis, and skin reactions.<xref ref-type="bibr" rid="article-109800.r38">[38]</xref></p>
        <p>Common adverse events related to TKIs are listed below. Not all adverse events are associated with every TKI, occurring at different frequencies depending on the drug.</p>
        <p>
<bold>&#x000a0;General</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fatigue</p>
          </list-item>
          <list-item>
            <p>Fevers/Chills</p>
          </list-item>
          <list-item>
            <p>Weight loss/gain</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Abdominal pain</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Dysgeusia</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Nausea/vomiting</p>
          </list-item>
          <list-item>
            <p>Hepatotoxicity</p>
          </list-item>
          <list-item>
            <p>Stomatitis</p>
          </list-item>
        </list>
        <p>
<bold>Cardiovascular</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Hypotension</p>
          </list-item>
          <list-item>
            <p>Congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Thrombosis</p>
          </list-item>
          <list-item>
            <p>Cardiac ischemia</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction</p>
          </list-item>
          <list-item>
            <p>Strokes</p>
          </list-item>
          <list-item>
            <p>Intestinal hemorrhage</p>
          </list-item>
          <list-item>
            <p>QT interval prolongation</p>
          </list-item>
        </list>
        <p>
<bold>Dermatological</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Steven Johnson syndrome</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis</p>
          </list-item>
          <list-item>
            <p>Drug rash with eosinophilia and systemic symptoms</p>
          </list-item>
          <list-item>
            <p>Acute generalized exanthematous pustulosis</p>
          </list-item>
          <list-item>
            <p>Palmar-plantar erythrodysesthesia</p>
          </list-item>
          <list-item>
            <p>Maculopapular rashes</p>
          </list-item>
          <list-item>
            <p>Cheilitis</p>
          </list-item>
          <list-item>
            <p>Facial edema</p>
          </list-item>
          <list-item>
            <p>Eczema</p>
          </list-item>
          <list-item>
            <p>Pruritis</p>
          </list-item>
          <list-item>
            <p>Photosensitivity</p>
          </list-item>
          <list-item>
            <p>Xerosis</p>
          </list-item>
          <list-item>
            <p>Alopecia</p>
          </list-item>
          <list-item>
            <p>Hair color changes</p>
          </list-item>
          <list-item>
            <p>Paronychia</p>
          </list-item>
        </list>
        <p>
<bold>Endocrine</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hypokalemia</p>
          </list-item>
          <list-item>
            <p>Thyroid dysfunction</p>
          </list-item>
          <list-item>
            <p>Lacrimation</p>
          </list-item>
        </list>
        <p>
<bold>Hematologic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Anemia</p>
          </list-item>
          <list-item>
            <p>Thrombocytopenia</p>
          </list-item>
          <list-item>
            <p>Neutropenia</p>
          </list-item>
          <list-item>
            <p>Bruising</p>
          </list-item>
        </list>
        <p>
<bold>Musculoskeletal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Myalgias</p>
          </list-item>
          <list-item>
            <p>Arthralgia</p>
          </list-item>
        </list>
        <p>
<bold>Ophthalmic</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Central serous retinopathy</p>
          </list-item>
          <list-item>
            <p>Retinal pigment epithelial detachment</p>
          </list-item>
          <list-item>
            <p>TKI keratitis</p>
          </list-item>
        </list>
        <p>
<bold>Renal</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Kidney dysfunction</p>
          </list-item>
          <list-item>
            <p>Proteinuria</p>
          </list-item>
        </list>
        <p>
<bold>Respiratory</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Interstitial pulmonary disease</p>
          </list-item>
          <list-item>
            <p>Pneumonia</p>
          </list-item>
          <list-item>
            <p>Upper respiratory tract infection</p>
          </list-item>
          <list-item>
            <p>Dyspnea</p>
          </list-item>
          <list-item>
            <p>Epistaxis</p>
          </list-item>
          <list-item>
            <p>Rhinorrhea</p>
          </list-item>
        </list>
        <p>
<bold>Neurological</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cognitive impairment</p>
          </list-item>
          <list-item>
            <p>Peripheral neuropathy</p>
          </list-item>
          <list-item>
            <p>Headaches</p>
          </list-item>
          <list-item>
            <p>Dizziness</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-109800.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are very few contraindications for TKIs. Considering the use of TKIs in life-extending cancer therapy, the benefits associated with TKI use generally outweigh the risks.<xref ref-type="bibr" rid="article-109800.r56">[56]</xref> Data concerning TKI use in pregnancy is sparse; however, with rising rates of advanced maternal-age pregnancies, cancers requiring TKI therapy during pregnancy have become more common.<xref ref-type="bibr" rid="article-109800.r57">[57]</xref><xref ref-type="bibr" rid="article-109800.r58">[58]</xref> While there are several reports of successfully administering TKIs, such as erlotinib, imatinib, and nilotinib, during pregnancy,&#x000a0;multiple studies demonstrate adverse events and teratogenic effects related to TKI use during pregnancy.<xref ref-type="bibr" rid="article-109800.r36">[36]</xref><xref ref-type="bibr" rid="article-109800.r59">[59]</xref><xref ref-type="bibr" rid="article-109800.r60">[60]</xref><xref ref-type="bibr" rid="article-109800.r61">[61]</xref></p>
        <p>Data on TKI use during pregnancy is still lacking in most cases. As a result, TKIs are typically co-prescribed with an effective contraception method during therapy and several weeks after discontinuing the TKI. Other limitations to using TKIs include severe adverse reactions. Patients at particular risk for one of the known adverse effects of the TKIs about to be prescribed, such as hypertension, interstitial lung disease, and long-QT syndrome, should receive an alternative therapy if possible.</p>
      </sec>
      <sec id="article-109800.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>While TKIs relieve the disease burden of most cancer patients, acquired resistance through various mechanisms remains a bottleneck in cancer targeted therapy. Patients require monitoring for disease progression after the initial benefit, which could be a sign of acquired resistance.<xref ref-type="bibr" rid="article-109800.r46">[46]</xref> Genetic testing to identify known resistance mutations can also help guide genotype-directed therapy.</p>
      </sec>
      <sec id="article-109800.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>TKIs are generally well-tolerated, especially when compared to non-targeted cancer therapy. However, only a few of these drugs are selective for only one target. Due to the ubiquitous physiological role protein kinases play in the body, toxicities affecting various organs can occur. Organs commonly affected include the heart, lungs, liver, gastrointestinal tract, kidneys, thyroid, blood, and skin.<xref ref-type="bibr" rid="article-109800.r62">[62]</xref></p>
        <p>The toxicity and efficacy of TKIs are often closely linked; this allows on-target toxic effects to act as biomarkers of effective pharmacological inhibition for certain TKIs. For example, skin rashes can serve&#x000a0;as a monitoring mechanism for the effects of some TKIs that target EGFR and hypertension and can generally help monitor the inhibition of VEGFR.<xref ref-type="bibr" rid="article-109800.r63">[63]</xref><xref ref-type="bibr" rid="article-109800.r64">[64]</xref><xref ref-type="bibr" rid="article-109800.r65">[65]</xref> However, the combined detrimental effects of both on-target and off-target toxicities can diminish a patient&#x02019;s quality of life and limit the dose intensity of their medication, leading to sub-therapeutic treatment.</p>
        <p>The optimal TKI of choice and dose is a requirement to reduce toxicities and adverse events. While TIKs are mainly administered at a fixed dose, several factors must guide dosing when devising an optimal TKI regimen. These factors include drug-drug/drug-food interactions, genetic polymorphisms of ABC transporters, patient adherence, intestinal absorption, distribution, metabolism, and elimination.<xref ref-type="bibr" rid="article-109800.r66">[66]</xref><xref ref-type="bibr" rid="article-109800.r67">[67]</xref> The interplay of multiple processes regulating the pharmacokinetics and pharmacodynamics of TKIs merits consideration when administering a TKI to titrate the optimal dosage.<xref ref-type="bibr" rid="article-109800.r68">[68]</xref></p>
      </sec>
      <sec id="article-109800.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The development of TKI represents one of the most significant medical breakthroughs of the 21st century; however, one of the drawbacks of this drug class, endemic to small molecule therapies for cancer treatment in general, is the financial burden to the patient.<xref ref-type="bibr" rid="article-109800.r1">[1]</xref> Kinase inhibitor therapy ranges from $5000&#x000a0;to $10,000 per month or more in the United States.<xref ref-type="bibr" rid="article-109800.r68">[68]</xref> The significant financial&#x000a0;burden may contribute to non-compliance resulting in disease progression and treatment resistance.<xref ref-type="bibr" rid="article-109800.r69">[69]</xref>&#x000a0;Clinicians, pharmacists, and other healthcare professionals should be aware of these financial burdens and discuss them along with the other potential physical toxicities of these drugs with the patient.</p>
        <p>Given the non-specific nature of this drug class, it is imperative that therapy is ordered and subsequently followed through the collaborative efforts of an interprofessional team. This interprofessional team includes clinicians (MDs, DOs, NPs, PAs), specialists, nursing staff, and pharmacists. Each team member needs to be knowledgeable about the indications, dosing, and potential adverse effects of these drugs so they can counsel the patient regarding expectations and monitoring for adverse events, which will allow any needed changes in therapy&#x000a0;to be made promptly,&#x000a0;thereby driving optimal patient therapeutic outcomes. [Level 5]</p>
      </sec>
      <sec id="article-109800.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=109800&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=109800">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/109800/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=109800">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-109800.s11">
        <title>References</title>
        <ref id="article-109800.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roskoski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.</article-title>
            <source>Pharmacol Res</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>152</volume>
            <fpage>104609</fpage>
            <pub-id pub-id-type="pmid">31862477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manning</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Whyte</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Martinez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hunter</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sudarsanam</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The protein kinase complement of the human genome.</article-title>
            <source>Science</source>
            <year>2002</year>
            <month>Dec</month>
            <day>06</day>
            <volume>298</volume>
            <issue>5600</issue>
            <fpage>1912</fpage>
            <page-range>1912-34</page-range>
            <pub-id pub-id-type="pmid">12471243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Clausen</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>FDA-approved small-molecule kinase inhibitors.</article-title>
            <source>Trends Pharmacol Sci</source>
            <year>2015</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>422</fpage>
            <page-range>422-39</page-range>
            <pub-id pub-id-type="pmid">25975227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Advances in studies of tyrosine kinase inhibitors and their acquired resistance.</article-title>
            <source>Mol Cancer</source>
            <year>2018</year>
            <month>Feb</month>
            <day>19</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <pub-id pub-id-type="pmid">29455664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patterson</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Brummer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Dual-specificity phosphatases: critical regulators with diverse cellular targets.</article-title>
            <source>Biochem J</source>
            <year>2009</year>
            <month>Mar</month>
            <day>15</day>
            <volume>418</volume>
            <issue>3</issue>
            <fpage>475</fpage>
            <page-range>475-89</page-range>
            <pub-id pub-id-type="pmid">19228121</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gebreyohannes</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wellens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cornillie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vanleeuw</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gardino</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lengauer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Debiec-Rychter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sciot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;ffski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.</article-title>
            <source>Clin Cancer Res</source>
            <year>2019</year>
            <month>Jan</month>
            <day>15</day>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>609</fpage>
            <page-range>609-618</page-range>
            <pub-id pub-id-type="pmid">30274985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vansteenkiste</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Van De Kerkhove</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wauters</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Van Mol</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Capmatinib for the treatment of non-small cell lung cancer.</article-title>
            <source>Expert Rev Anticancer Ther</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>659</fpage>
            <page-range>659-671</page-range>
            <pub-id pub-id-type="pmid">31368815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>PCC</given-names>
              </name>
              <name>
                <surname>Koblish</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bowman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Diamond</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DiMatteo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hansbury</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rupar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Collier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Klabe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burke</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Soloviev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gardiner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Volgina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Covington</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wynn</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burn</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Scherle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yeleswaram</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Huber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hollis</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>e0231877</fpage>
            <pub-id pub-id-type="pmid">32315352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mazzocca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silletta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spalato Ceruso</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tonini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vincenzi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>New frontiers in the medical management of gastrointestinal stromal tumours.</article-title>
            <source>Ther Adv Med Oncol</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>1758835919841946</fpage>
            <pub-id pub-id-type="pmid">31205499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markham</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Selpercatinib: First Approval.</article-title>
            <source>Drugs</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>80</volume>
            <issue>11</issue>
            <fpage>1119</fpage>
            <page-range>1119-1124</page-range>
            <pub-id pub-id-type="pmid">32557397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dombi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Whitcomb</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aschbacher-Smith</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Rizvi</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ershler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wolters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Therrien</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Glod</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belasco</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Schorry</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brofferio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Starosta</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doyle</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Widemann</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Dec</month>
            <day>29</day>
            <volume>375</volume>
            <issue>26</issue>
            <fpage>2550</fpage>
            <page-range>2550-2560</page-range>
            <pub-id pub-id-type="pmid">28029918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tucatinib: First Approval.</article-title>
            <source>Drugs</source>
            <year>2020</year>
            <month>Jul</month>
            <volume>80</volume>
            <issue>10</issue>
            <fpage>1033</fpage>
            <page-range>1033-1038</page-range>
            <pub-id pub-id-type="pmid">32548668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rolfo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ruiz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giovannetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gil-Bazo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Passiglia</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Giallombardo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raez</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.</article-title>
            <source>Expert Opin Investig Drugs</source>
            <year>2015</year>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>1493</fpage>
            <page-range>1493-500</page-range>
            <pub-id pub-id-type="pmid">26457764</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marandino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raggi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Giannatempo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Far&#x000e8;</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Necchi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Erdafitinib for the treatment of urothelial cancer.</article-title>
            <source>Expert Rev Anticancer Ther</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>835</fpage>
            <page-range>835-846</page-range>
            <pub-id pub-id-type="pmid">31544541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bewersdorf</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Jaszczur</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Afifi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Zeidan</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.</article-title>
            <source>Cancer Manag Res</source>
            <year>2019</year>
            <volume>11</volume>
            <fpage>10777</fpage>
            <page-range>10777-10790</page-range>
            <pub-id pub-id-type="pmid">31920387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamb</surname>
                <given-names>YN</given-names>
              </name>
            </person-group>
            <article-title>Pexidartinib: First Approval.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>79</volume>
            <issue>16</issue>
            <fpage>1805</fpage>
            <page-range>1805-1812</page-range>
            <pub-id pub-id-type="pmid">31602563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duggan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Keam</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Upadacitinib: First Approval.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>79</volume>
            <issue>16</issue>
            <fpage>1819</fpage>
            <page-range>1819-1828</page-range>
            <pub-id pub-id-type="pmid">31642025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>YY</given-names>
              </name>
            </person-group>
            <article-title>Zanubrutinib: First Approval.</article-title>
            <source>Drugs</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>80</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-97</page-range>
            <pub-id pub-id-type="pmid">31933167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reddy</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>JAK Inhibitors: What Is New?</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2020</year>
            <month>Jul</month>
            <day>22</day>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">32700001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Queirolo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spagnolo</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Binimetinib for the treatment of NRAS-mutant melanoma.</article-title>
            <source>Expert Rev Anticancer Ther</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>985</fpage>
            <page-range>985-990</page-range>
            <pub-id pub-id-type="pmid">28851243</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology.</article-title>
            <source>Drug Saf</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-198</page-range>
            <pub-id pub-id-type="pmid">30649743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bussel</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Fostamatinib for persistent/chronic adult immune thrombocytopenia.</article-title>
            <source>Immunotherapy</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-25</page-range>
            <pub-id pub-id-type="pmid">28967793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia.</article-title>
            <source>Biomark Res</source>
            <year>2019</year>
            <volume>7</volume>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">31528345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Larotrectinib: First Global Approval.</article-title>
            <source>Drugs</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>201</fpage>
            <page-range>201-206</page-range>
            <pub-id pub-id-type="pmid">30635837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-178</page-range>
            <pub-id pub-id-type="pmid">30657349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ren</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thareja</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.</article-title>
            <source>Eur J Med Chem</source>
            <year>2018</year>
            <month>May</month>
            <day>10</day>
            <volume>151</volume>
            <fpage>315</fpage>
            <page-range>315-326</page-range>
            <pub-id pub-id-type="pmid">29631132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Manley</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Capdeville</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.</article-title>
            <source>Blood Adv</source>
            <year>2018</year>
            <month>Feb</month>
            <day>27</day>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>444</fpage>
            <page-range>444-453</page-range>
            <pub-id pub-id-type="pmid">29487059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Alectinib: A Review in Advanced, ALK-Positive NSCLC.</article-title>
            <source>Drugs</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>78</volume>
            <issue>12</issue>
            <fpage>1247</fpage>
            <page-range>1247-1257</page-range>
            <pub-id pub-id-type="pmid">30030733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Signorelli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shah Gandhi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cobimetinib.</article-title>
            <source>Ann Pharmacother</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-153</page-range>
            <pub-id pub-id-type="pmid">27701080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabanillas</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Habra</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Lenvatinib: Role in thyroid cancer and other solid tumors.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>42</volume>
            <fpage>47</fpage>
            <page-range>47-55</page-range>
            <pub-id pub-id-type="pmid">26678514</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solassol</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pinguet</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Quantin</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced <italic>EGFR</italic>-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management.</article-title>
            <source>Biomolecules</source>
            <year>2019</year>
            <month>Oct</month>
            <day>30</day>
            <volume>9</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">31671561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaw</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Engelman</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Ceritinib in ALK-rearranged non-small-cell lung cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2014</year>
            <month>Jun</month>
            <day>26</day>
            <volume>370</volume>
            <issue>26</issue>
            <fpage>2537</fpage>
            <page-range>2537-9</page-range>
            <pub-id pub-id-type="pmid">24963575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varone</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sgalla</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iovene</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bruni</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Richeldi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Nintedanib for the treatment of idiopathic pulmonary fibrosis.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-175</page-range>
            <pub-id pub-id-type="pmid">29327616</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeiser</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Andrlov&#x000e1;</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meiss</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Trametinib (GSK1120212).</article-title>
            <source>Recent Results Cancer Res</source>
            <year>2018</year>
            <volume>211</volume>
            <fpage>91</fpage>
            <page-range>91-100</page-range>
            <pub-id pub-id-type="pmid">30069762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellesoeur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carton</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alexandre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldwasser</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Huillard</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.</article-title>
            <source>Drug Des Devel Ther</source>
            <year>2017</year>
            <volume>11</volume>
            <fpage>2801</fpage>
            <page-range>2801-2811</page-range>
            <pub-id pub-id-type="pmid">29033542</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Abboud</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Bhatnagar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>DeAngelo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Gotlib</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hagelstrom</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jagasia</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kropf</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Metheny</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Ontiveros</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Purev</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Quiery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>VV</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Tibes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Gregory</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sundar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Deininger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Radich</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>14</volume>
            <issue>12</issue>
            <fpage>1505</fpage>
            <page-range>1505-1512</page-range>
            <pub-id pub-id-type="pmid">27956535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Doroshow</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kummar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>United States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignancies.</article-title>
            <source>Curr Probl Cancer</source>
            <year>2013</year>
            <season>May-Jun</season>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>110</fpage>
            <page-range>110-44</page-range>
            <pub-id pub-id-type="pmid">23972982</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lankhorst</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Danser</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>van den Meiracker</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Endothelin-1 and antiangiogenesis.</article-title>
            <source>Am J Physiol Regul Integr Comp Physiol</source>
            <year>2016</year>
            <month>Feb</month>
            <day>01</day>
            <volume>310</volume>
            <issue>3</issue>
            <fpage>R230</fpage>
            <page-range>R230-4</page-range>
            <pub-id pub-id-type="pmid">26511523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhullar</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Lagar&#x000f3;n</surname>
                <given-names>NO</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Parmar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hubbard</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Rupasinghe</surname>
                <given-names>HPV</given-names>
              </name>
            </person-group>
            <article-title>Kinase-targeted cancer therapies: progress, challenges and future directions.</article-title>
            <source>Mol Cancer</source>
            <year>2018</year>
            <month>Feb</month>
            <day>19</day>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <pub-id pub-id-type="pmid">29455673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kolibaba</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Druker</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Protein tyrosine kinases and cancer.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>1997</year>
            <month>Dec</month>
            <day>09</day>
            <volume>1333</volume>
            <issue>3</issue>
            <fpage>F217</fpage>
            <page-range>F217-48</page-range>
            <pub-id pub-id-type="pmid">9426205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seeliger</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Targeting conformational plasticity of protein kinases.</article-title>
            <source>ACS Chem Biol</source>
            <year>2015</year>
            <month>Jan</month>
            <day>16</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>190</fpage>
            <page-range>190-200</page-range>
            <pub-id pub-id-type="pmid">25486330</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Toader</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Structural approaches to obtain kinase selectivity.</article-title>
            <source>Trends Pharmacol Sci</source>
            <year>2012</year>
            <month>May</month>
            <volume>33</volume>
            <issue>5</issue>
            <fpage>273</fpage>
            <page-range>273-8</page-range>
            <pub-id pub-id-type="pmid">22503441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lamba</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.</article-title>
            <source>Curr Pharm Des</source>
            <year>2012</year>
            <volume>18</volume>
            <issue>20</issue>
            <fpage>2936</fpage>
            <page-range>2936-45</page-range>
            <pub-id pub-id-type="pmid">22571662</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wind</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schnell</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ebner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Freiwald</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stopfer</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetics and Pharmacodynamics of Afatinib.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>56</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-250</page-range>
            <pub-id pub-id-type="pmid">27470518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kucharczuk</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ganetsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vozniak</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.</article-title>
            <source>J Adv Pract Oncol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>189</fpage>
            <page-range>189-200</page-range>
            <pub-id pub-id-type="pmid">30588353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Camidge</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Pao</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sequist</surname>
                <given-names>LV</given-names>
              </name>
            </person-group>
            <article-title>Acquired resistance to TKIs in solid tumours: learning from lung cancer.</article-title>
            <source>Nat Rev Clin Oncol</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>11</volume>
            <issue>8</issue>
            <fpage>473</fpage>
            <page-range>473-81</page-range>
            <pub-id pub-id-type="pmid">24981256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Himanshu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Imatinib-induced Stevens-Johnsons syndrome.</article-title>
            <source>BMJ Case Rep</source>
            <year>2013</year>
            <month>Jan</month>
            <day>23</day>
            <volume>2013</volume>
            <pub-id pub-id-type="pmid">23349042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.</article-title>
            <source>J Immunol Res</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>5376476</fpage>
            <pub-id pub-id-type="pmid">29577050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kao</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies.</article-title>
            <source>Cancer Manag Res</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>1259</fpage>
            <page-range>1259-1273</page-range>
            <pub-id pub-id-type="pmid">29844705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrara</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Vascular endothelial growth factor: basic science and clinical progress.</article-title>
            <source>Endocr Rev</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>581</fpage>
            <page-range>581-611</page-range>
            <pub-id pub-id-type="pmid">15294883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmeliet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Breier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pollefeyt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kieckens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gertsenstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fahrig</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vandenhoeck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harpal</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eberhardt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Declercq</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pawling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moons</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Collen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Risau</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Nagy</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele.</article-title>
            <source>Nature</source>
            <year>1996</year>
            <month>Apr</month>
            <day>04</day>
            <volume>380</volume>
            <issue>6573</issue>
            <fpage>435</fpage>
            <page-range>435-9</page-range>
            <pub-id pub-id-type="pmid">8602241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of adverse effects of anti-VEGF therapy for cancer.</article-title>
            <source>Br J Cancer</source>
            <year>2007</year>
            <month>Jun</month>
            <day>18</day>
            <volume>96</volume>
            <issue>12</issue>
            <fpage>1788</fpage>
            <page-range>1788-95</page-range>
            <pub-id pub-id-type="pmid">17519900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Escalante</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Zalpour</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers.</article-title>
            <source>Cardiol Res Pract</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>816897</fpage>
            <pub-id pub-id-type="pmid">21629798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horowitz</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rivard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van der Zee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hariawala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sheriff</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Esakof</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Symes</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Isner</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>1997</year>
            <month>Nov</month>
            <volume>17</volume>
            <issue>11</issue>
            <fpage>2793</fpage>
            <page-range>2793-800</page-range>
            <pub-id pub-id-type="pmid">9409257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kilickap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abali</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Celik</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Bevacizumab, bleeding, thrombosis, and warfarin.</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Sep</month>
            <day>15</day>
            <volume>21</volume>
            <issue>18</issue>
            <fpage>3542; author reply 3543</fpage>
            <pub-id pub-id-type="pmid">12972536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rivas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Llin&#x000e1;s</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bonilla</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rubiano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cuello</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Arango</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.</article-title>
            <source>Lung Cancer</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>469</fpage>
            <page-range>469-72</page-range>
            <pub-id pub-id-type="pmid">22534670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
            </person-group>
            <article-title>Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.</article-title>
            <source>Oncologist</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>e1141</fpage>
            <page-range>e1141-e1147</page-range>
            <pub-id pub-id-type="pmid">31186377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hartford</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramsey</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verschraegen</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.</article-title>
            <source>JAMA Oncol</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>6</issue>
            <fpage>838</fpage>
            <page-range>838-40</page-range>
            <pub-id pub-id-type="pmid">26181671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Druker</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Burwick</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>20</day>
            <volume>36</volume>
            <issue>12</issue>
            <fpage>1250</fpage>
            <page-range>1250-1256</page-range>
            <pub-id pub-id-type="pmid">29447062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cortes</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Abruzzese</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chelysheva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guha</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wallis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Apperley</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>The impact of dasatinib on pregnancy outcomes.</article-title>
            <source>Am J Hematol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>90</volume>
            <issue>12</issue>
            <fpage>1111</fpage>
            <page-range>1111-5</page-range>
            <pub-id pub-id-type="pmid">26348106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pye</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ault</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hatfield</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pilot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Apperley</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>The effects of imatinib on pregnancy outcome.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Jun</month>
            <day>15</day>
            <volume>111</volume>
            <issue>12</issue>
            <fpage>5505</fpage>
            <page-range>5505-8</page-range>
            <pub-id pub-id-type="pmid">18322153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fujita</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Ishida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sasaki</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.</article-title>
            <source>Curr Drug Metab</source>
            <year>2017</year>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>186</fpage>
            <page-range>186-198</page-range>
            <pub-id pub-id-type="pmid">28059038</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petrelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Borgonovo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cabiddu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lonati</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Barni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.</article-title>
            <source>Lung Cancer</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-15</page-range>
            <pub-id pub-id-type="pmid">22795701</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Estfan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Byrne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.</article-title>
            <source>Am J Clin Oncol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>36</volume>
            <issue>4</issue>
            <fpage>319</fpage>
            <page-range>319-24</page-range>
            <pub-id pub-id-type="pmid">22547010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamnvik</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Choueiri</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Turchin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kaymakcalan</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.</article-title>
            <source>Cancer</source>
            <year>2015</year>
            <month>Jan</month>
            <day>15</day>
            <volume>121</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-9</page-range>
            <pub-id pub-id-type="pmid">25236375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kl&#x000fc;mpen</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Samer</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Mathijssen</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Schellens</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Gurney</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Moving towards dose individualization of tyrosine kinase inhibitors.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-60</page-range>
            <pub-id pub-id-type="pmid">20833478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Noda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Inui</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.</article-title>
            <source>Pharmacol Ther</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>152</volume>
            <fpage>125</fpage>
            <page-range>125-34</page-range>
            <pub-id pub-id-type="pmid">25976912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roskoski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Properties of FDA-approved small molecule protein kinase inhibitors.</article-title>
            <source>Pharmacol Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>144</volume>
            <fpage>19</fpage>
            <page-range>19-50</page-range>
            <pub-id pub-id-type="pmid">30877063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-109800.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dusetzina</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Winn</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Abel</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Huskamp</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Keating</surname>
                <given-names>NL</given-names>
              </name>
            </person-group>
            <article-title>Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.</article-title>
            <source>J Clin Oncol</source>
            <year>2014</year>
            <month>Feb</month>
            <day>01</day>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-11</page-range>
            <pub-id pub-id-type="pmid">24366936</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
